Antiviral Combination Therapies Market, By Drug Combination (RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI and NRTI/Protease Inhibitor), By Product (Branded and Generic), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies), By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Antiviral Combination Therapies Market size was valued at USD 46,806 Million in 2022, expanding at a CAGR of 4.8% from 2023 to 2030.
Antiviral combination therapies, also known as Composite Antiviral Therapy (CAT), involve the simultaneous administration of multiple antiviral medications for the treatment of viral infections. This approach entails the strategic combination of diverse antiviral drugs, each targeting distinct stages of the viral replication cycle or specific viral strains. The primary objective is to enhance treatment effectiveness and reduce the likelihood of drug resistance development. The utilization of antiviral aggregate treatment is imperative due to the rapid mutation rates often exhibited by viruses, enabling them to swiftly adapt and develop resistance when confronted with single-agent therapies.
Antiviral Combination Therapies Market- Market Dynamics
- The growing prevalence of viral infection drives the market growth
The increasing prevalence of viral infections worldwide is expected to boost market growth. Viral illnesses such as HIV/AIDS, hepatitis, COVID-19, influenza, and herpes affect a significant portion of the global population annually. Antiviral combination therapies offer several advantages over single-drug treatments, including the ability to delay or prevent drug resistance development. They have become the standard for treating chronic viral diseases like HCV and HIV. These therapies are crucial in managing HIV, reducing drug resistance, and limiting virus transmission. Additionally, they effectively treat acute viral infections like influenza, reducing drug resistance, curbing viral replication, improving efficiency, and lowering mortality rates, as noted by NCBI. This trend is anticipated to drive market growth.
Antiviral Combination Therapies Market- Key Insights
- As per the analysis shared by our research analyst, the global Antiviral Combination Therapies market is estimated to grow annually at a CAGR of around 4.8% over the forecast period (2023-2030)
- The antiviral Combination Therapies industry is projected to grow at a significant rate owing to the growing prevalence of viral infection.
- Based on the drug combination, the RTI/NNRTI segment is expected to dominate the market during the forecast period.
- Based on region, North America is expected to dominate the market over the forecast period.
Antiviral Combination Therapies Market- Segmentation Analysis:
The Global Antiviral Combination Therapies Market is segmented based on Drug Combination, Product, Distribution Channel and Region.
The global Antiviral Combination Therapies market is categorized into segments based on drug combinations, including RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others. The RTI/NNRTI segment is expected to lead the market due to its significance in antiviral combination therapy, particularly in HIV/AIDS treatment. This segment plays a crucial role in halting viral replication. Furthermore, NRTIs, a subset of RTIs, act as nucleoside analogs, mimicking natural nucleotides in viral DNA chains to inhibit viral DNA production effectively.
Antiviral Combination Therapies Market- Geographical Insights
The Antiviral Combination Therapies market spans North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa, with further subdivisions by country. North America is poised to lead the market due to rising cases of HIV, Hepatitis, Influenza, and more. The presence of major pharmaceutical companies and ongoing research and development projects will contribute to its growth. Meanwhile, the Asia Pacific is expected to register the highest growth rate, driven by a burgeoning pharmaceutical industry and government initiatives.
Antiviral Combination Therapies Market- Competitive Landscape:
Key players in the market include Merck & Co. Inc., ViiV Healthcare, Gilead Sciences Inc., AbbVie Inc., Janssen Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals Inc., Roche Holding AG, Mylan N.V., and Cipla Ltd. For instance, in February 2023, Atea Pharmaceuticals announced significant findings from a Phase 2 clinical study of AT-527, a COVID-19 treatment. AT-527, a small molecule, disrupts the entry mechanism of the SARS-CoV-2 virus. This breakthrough has the potential to positively impact the commercial landscape for antiviral combination treatments.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET KEY PLAYERS
- Merck & Co. Inc.
- ViiV Healthcare
- Gilead Sciences Inc.
- AbbVie Inc.
- Janssen Pharmaceuticals
- Bristol Myers Squibb
- Boehringer Ingelheim Pharmaceuticals Inc.
- Roche Holding AG
- Mylan N.V.
- Cipla Ltd.
GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DRUG COMBINATION
- RTI/NNRTI
- Integrase Inhibitor/NRTI
- NRTI
- NRTI/Protease Inhibitor
- Others
GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY PRODUCT
- Branded
- Generic
GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Others
GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Antiviral Combination Therapies Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Antiviral Combination Therapies Market Snippet by Drug Combination
2.1.2. Antiviral Combination Therapies Market Snippet by Product
2.1.3. Antiviral Combination Therapies Market Snippet by Distribution Channel
2.1.4. Antiviral Combination Therapies Market Snippet by Country
2.1.5. Antiviral Combination Therapies Market Snippet by Region
2.2. Competitive Insights
3. Antiviral Combination Therapies Key Market Trends
3.1. Antiviral Combination Therapies Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Antiviral Combination Therapies Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Antiviral Combination Therapies Market Opportunities
3.4. Antiviral Combination Therapies Market Future Trends
4. Antiviral Combination Therapies Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Antiviral Combination Therapies Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Antiviral Combination Therapies Market Landscape
6.1. Antiviral Combination Therapies Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Antiviral Combination Therapies Market – By Drug Combination
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Combination, 2022 & 2030 (%)
7.1.2. RTI/NNRTI
7.1.3. Integrase Inhibitor/NRTI
7.1.4. NRTI
7.1.5. NRTI/Protease Inhibitor
7.1.6. Others
8. Antiviral Combination Therapies Market – By Product
8.1. Overview
8.1.1. Segment Share Analysis, By Product, 2022 & 2030 (%)
8.1.2. Branded
8.1.3. Generic
9. Antiviral Combination Therapies Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
9.1.2. Hospital Pharmacies
9.1.3. Retail Pharmacies
9.1.4. Others
10. Antiviral Combination Therapies Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Antiviral Combination Therapies Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Antiviral Combination Therapies Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Antiviral Combination Therapies Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Antiviral Combination Therapies Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Antiviral Combination Therapies Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Antiviral Combination Therapies Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Merck & Co. Inc.
11.2.2. ViiV Healthcare
11.2.3. Gilead Sciences Inc.
11.2.4. AbbVie Inc.
11.2.5. Janssen Pharmaceuticals
11.2.6. Bristol Myers Squibb
11.2.7. Boehringer Ingelheim Pharmaceuticals Inc.
11.2.8. Roche Holding AG
11.2.9. Mylan N.V.
11.2.10. Cipla Ltd.
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
